Ann: Quarterly Activities Report and Appendix 4C, page-5

New, but not material . Be interesting to see if anyone does want to pick up ATL1101/ATL1102, and ATL1103 down the road . Genandi et al thought it was only the trial that was flawed, not the drug, well that was their excuse to try and take the company of us anyway.

Really like the way Garner talks about things. Very clear & professional. PER mark 2 won't fail due to lack of effort and that's all we can ask for at this end of the market

Technically 1.0/1.2 is ferocious resistance, and PVL selling still around , so could be stuck in a 0.008 to 0.012 range for a while yet.